## TriLink BioTechnologies Analytical Services

Analytical testing is a critical component of every manufacturing program. As a CDMO with an ISO 9001:2015 certification and ICH Q7 Section 19 compliant quality system, we understand that successful biotherapeutic development and manufacturing are supported by comprehensive testing. We offer unparalleled expertise in phase-appropriate method development and analytical testing to further support your mRNA, plasmid, small molecule and oligonucleotide manufacturing process.

# Accelerate Your Product Development with Optimized Testing Services

With over 20 years of experience, we understand your analytical objectives from process development (PD) to scale-up and cGMP manufacturing. TriLink has developed extensive capabilities in **custom method development** and **analytical testing** to ensure a high quality manufacturing process. We work with you to ensure effective method development that meets your objectives at each stage of product development.



### Plasmid

### Active Moiety Quantification:

 Concentration and Purity (UV Spec), % Supercoiled

### Identification:

• Sequencing, Restriction Digest Pattern

### Safety (Microbial):

• Endotoxin, Bioburden

### Impurity Quantification:

• Residual Protein, Residual gDNA, Isoform Analysis & % RNA (HPLC)

### Product Characterization:

Appearance

### Oligonucleotide

### Active Moiety Quantification:

• HPLC, Concentration (UV-Vis)

### Identification:

• MS, Retention Time

### Purity:

• IP-RP HPLC, AX-HPLC

### Safety (Microbial):

• Endotoxin, Bioburden

### Impurity Quantification:

• Residual Solvents, ICP-MS

### Product Characterization:

• Karl Fischer, Thermal Properties [Solution], NMR, Dynamic Vapor Sorption [Lyophilized]

### mRNA

### Active Moiety Quantification: • Concentration

### Identification:

• Sanger Sequencing, PCR, Length, *In Vitro* Translation, RNase Digestion, Analytical Transcription

### Safety (Microbial):

• Endotoxin, Bioburden, Mycoplasma

### Impurity Quantification:

• Residual Protein, Residual DNA, Residual Solvents

### Qualitative Assessment:

• Residual dsRNA, Residual Protein, Agarose Gel, DNase and RNase Detection

### Product Characterization:

• Appearance, pH, Osmolality, Conductivity, Poly A Tail Length, Capping Efficiency, Integrity



### NTPs, CleanCap<sup>®</sup> and Other Cap Analogs

### Active Moiety Quantification: • Concentration (UV-Vis)

### Identification:

• MS, <sup>1</sup>H NMR

### **Purity:**

• IP-RP HPLC, AX-HPLC, <sup>31</sup>P NMR

### Safety (Microbial):

• Endotoxin, Bioburden

### Qualitative Assessment:

• DNase and RNase Detection, Transcription Functional Test

### Product Characterization:

• Conductivity, pH

Products containing CleanCap technology are for research use only. License is required for commercial use of CleanCap and CleanCap Products. For license restrictions and patent(s) information, refer to https://www.trilinkbiotech.com/legal-notices

10770 Wateridge Circle, Suite 200 San Diego, CA 92121 800.863.6801 | info@trilinkbiotech.com | trilinkbiotech.com



Distributed by Abacus dx 1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

